Table of Contents
SARS-CoV-2/COVID-19 Natural Immunity
T Cell Immunity
Both symptomatic and asymptomatic SARS-CoV-2 infections result in T cell responses, with greater interferon-\alpha producing responses from those with symptomatic infections.1)
“SARS-CoV-2-naïve vaccinees had a 13.06-fold (95% CI, 8.08 to 21.11) increased risk for breakthrough infection with the Delta variant compared to those previously infected, when the first event (infection or vaccination) occurred during January and February of 2021.” Gazit et al., August 2021.2)
Iliaki et al found zero reinfections in a study of urban health care workers.3)
Majdoubi, Michalski et al demonstrated the existence of cross-reactive antibodies as far back as May 2020, and concluded that more than 90% of uninfected adults showed antibody reactivity against the spike protein, receptor-binding domain (RBD), N-terminal domain (NTD), or the nucleocapsid (N) protein from SARS-CoV-2. This seroreactivity was evenly distributed across age and sex, correlated with circulating coronaviruses’ reactivity, and was partially outcompeted by soluble circulating coronaviruses’ spike.4)
Comparisons of Empirical Studies
Critique of Empirical Research
Quick Listing of Supportive Articles/Publications to Share
- On January 6, 2021 the NCAA updated their Covid protocols and now consider student athletes to be “fully vaccinated” if they are within 90 days of a documented covid-19 infection.
- The WHO Scientific Brief on natural immunity concludes that “Current evidence points to most individuals developing strong protective immune responses following natural infection with SARSCoV-2.”
- The EU Digital COVID Certificate recognizes natural immunity for 180 days.
The Center for Disease Control and Prevention has abandoned all pretense that it is other than a government-funded public relations arm of the pharmaceutical industry during the pandemic. The topic of natural immunity makes this reality most plain.6)7)